Fig. 6. Ad5-3M transduces primary NSCLC tumors, suppresses tumor growth, and extends survival of PDX tumor-bearing mice after systemic administration.

(A) Fluorescent images of virus-driven GFP expression in primary NSCLC PDX tumor explants 3-5 days after Ad5-3M infection. Representative images of virus transduction for four individual PDX models are shown. In vivo BLI of NSCLC PDX models TM00302 (B) and TM00784 (C) subcutaneously grafted to NSG mice and treated with Ad5-3M intravenously. The color indicates intensity of luminescence of virus-encoded nano-luciferase. (D) Amounts of viral genomic DNA in TM00302-derived PDX tumors at the indicated times post intravenous Ad5-3M administration (n = 2-8). (E) Activity of virus-encoded nano-luciferase in subcutaneous TM00784 PDX tumors at the indicated time points after intravenous Ad5-3M administration (n = 4-12). (F) Fluorescent images of sections of PDX-tumors harvested from mice treated with Ad5-3M or buffer. Virus-driven GFP expression is in green and necrotic propidium iodide (PI)-positive cells are in red. The anatomical boundaries of tumor nodules are depicted with dotted lines. (G) Kinetics of tumor growth and (H) Log-rank survival plot of TM00302 PDX-tumor-bearing mice treated with Ad5-WT (n = 5), Ad5-3M (n = 10), or Buffer (n = 9). (I) Kinetics of tumor growth and (J) log-rank survival plot of TM00784 PDX-tumor-bearing mice treated with Ad5-WT (n = 5), Ad5-3M (n = 10), or buffer (n = 8). The blue crosses indicated death of the animals treated with Ad5-WT. The color of the p-value number indicates the comparison partner to Buffer group. The methodology and statistical details are as described in Table S1 and Methods.